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Abstract
Background: Two trials were conducted to compare emergency department patient comprehension of
rapid HIV pre-test information using different methods to deliver this information.
Methods: Patients were enrolled for these two trials at a US emergency department between February
2005 and January 2006. In Trial One, patients were randomized to a no pre-test information or an in-
person discussion arm. In Trial Two, a separate group of patients were randomized to an in-person
discussion arm or a Tablet PC-based video arm. The video, "Do you know about rapid HIV testing?", and
the in-person discussion contained identical Centers for Disease Control and Prevention-suggested pre-
test information components as well as information on rapid HIV testing with OraQuick®. Participants
were compared by information arm on their comprehension of the pre-test information by their score on
a 26-item questionnaire using the Wilcoxon rank-sum test.
Results: In Trial One, 38 patients completed the no-information arm and 31 completed the in-person
discussion arm. Of these 69 patients, 63.8% had twelve years or fewer of formal education and 66.7% had
previously been tested for HIV. The mean score on the questionnaire for the in-person discussion arm
was higher than for the no information arm (18.7 vs. 13.3, p ≤ 0.0001). In Trial Two, 59 patients completed
the in-person discussion and 55 completed the video arms. Of these 114 patients, 50.9% had twelve years
or fewer of formal education and 68.4% had previously been tested for HIV. The mean score on the
questionnaire for the video arm was similar to the in-person discussion arm (20.0 vs. 19.2; p ≤ 0.33).
Conclusion: The video "Do you know about rapid HIV testing?" appears to be an acceptable substitute
for an in-person pre-test discussion on rapid HIV testing with OraQuick®. In terms of adequately informing
ED patients about rapid HIV testing, either form of pre-test information is preferable than for patients to
receive no pre-test information.
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Background
According to CDC estimates, there were 1,039,000–
1,185,000 persons living with an HIV infection in the
United States as of 2003 [1]. Of these, at least 25% are
infected with HIV and are unaware of their infection. To
help those infected with HIV learn their HIV status, the
Centers for Disease Control and Prevention (CDC) advo-
cate expanding HIV testing in non-traditional test settings,
such as emergency departments (EDs) [2,3]. Rapid HIV
testing might further reduce the number of persons una-
ware of their HIV status by streamlining the HIV testing
process and by making HIV testing more readily available
in a variety of locations. In September 2006, the CDC
released new guidelines on HIV testing for healthcare set-
tings [3]. To help facilitate HIV testing, the CDC recom-
mended that traditional pre-test counseling be simplified
by separating the routine requirement for pre-test infor-
mation from the as needed provision of prevention coun-
seling.
One limitation of HIV testing in non-traditional settings is
the difficulty of effectively providing pre-test information
to those undergoing testing. In a busy ED, it can be chal-
lenging for staff to adequately give patients CDC-recom-
mended components of HIV pre-test information. The
open-space environment of EDs, the numerous distrac-
tions and noises, the sometimes critical nature of patient
visits, and staff time limitations make it difficult to edu-
cate patients about HIV and HIV testing. In addition, staff
knowledge about HIV testing varies, so information pre-
sented to patients might not be uniform and sometimes
might not be accurate. Although written information is a
potential alternative to an in-person discussion, this
might not be adequate for all patients, given wide varia-
tions in patient reading abilities.
One approach to address limitations of staff availability
and to ensure standardization of HIV pre-test information
is through the use of a patient educational video in lieu of
an in-person discussion. Videos have been recommended
or used as an adjunct to pre-test information or as substi-
tutes for in-person discussion for standard (as opposed to
rapid) HIV testing [4-8]. However, there have been few
studies evaluating their effectiveness in providing this
information, particularly as compared to an in-person dis-
cussion. Calderon, et al. created a video for standard HIV
testing at the Jacobi ED in New York in response to a lack
of HIV counselors after normal business hours [9]. Using
a questionnaire developed by the authors, they observed
that patients watching the video demonstrated greater
knowledge (a 7% higher mean score) about standard HIV
testing than those receiving information from an HIV test
counselor. To our knowledge, there have been no studies
in any setting evaluating the utility of a rapid HIV educa-
tional video as a substitute for in-person discussions
about rapid HIV testing.
Prior to the release of the new CDC HIV testing guidelines,
we conducted two randomized controlled trials compar-
ing different methods of delivering rapid HIV pre-test
information to adult ED patients. We assessed patient
comprehension of rapid HIV pre-test information using a
questionnaire. In Trial One, we compared patient com-
prehension using this questionnaire among patients ran-
domized to receive no pre-test information to those
randomized to receive an in-person discussion about
rapid HIV testing from an HIV test counselor. In Trial Two,
we compared a separate group of patients who were rand-
omized to an in-person discussion to those randomized
to receive HIV pre-test information from the educational
video, "Do you know about rapid HIV testing?"[10] The
video and the in-person discussion contained the same
CDC-recommended elements on pre-test HIV informa-
tion as well as the same information specific to rapid HIV
testing with OraQuick®. The goal of this pilot study was to
evaluate these methods of pre-test information delivery
prior to the conduct of a larger randomized controlled
trial that included performing rapid HIV testing.
Methods
Study design
Two randomized controlled trials were conducted that
examined different methods of rapid HIV testing informa-
tion delivery. The trials were conducted sequentially. For
both trials, participant understanding of rapid HIV testing
fundamentals was evaluated using a questionnaire. The
first trial compared participants who received no informa-
tion to those who underwent an in-person discussion. The
second trial compared participants who underwent an in-
person discussion to those who watched an educational
video. The Rhode Island Hospital institutional review
board (IRB) approved the study. This study was a pilot to
a larger trial comparing the video to the in-person discus-
sion information delivery methods among patients
undergoing rapid HIV testing with OraQuick®.
Study population and eligibility
The two trials were performed at the Rhode Island Hospi-
tal ED, which is a large, urban, academic ED in the north-
eastern US. Patients eligible for the trials were ED patients
18-55-years-old who were not pregnant; not incarcerated
or in home confinement; not known to be HIV infected;
able to speak, read, and write in English; were not deaf;
and were not critically ill, intoxicated, or presenting to the
ED for a psychiatric problem. Participants could only be
members of one trial.BMC Public Health 2007, 7:238 http://www.biomedcentral.com/1471-2458/7/238
Page 3 of 12
(page number not for citation purposes)
Study conduct
Trial One was conducted February-April 2005 and Trial
Two between April 2005-January 2006. A research assist-
ant (RA) conducted the trials weekdays during arbitrarily
selected eight-hour shifts. The shifts began between 7 a.m.
and 3 p.m. and ended between 3 p.m. and 11 p.m. For
each trial, a research assistant (RA) randomly screened for
study eligibility 50% of the medical records of patients
who were present in the ED during the RA's shift. Before
each shift, the RA used a random number generator to
choose either the number 1 or 2 [11]. These numbers rep-
resented "odd" and "even" terminal medical record digits,
respectively. The RAs screened only the "odd" or the
"even" medical records for that shift as determined by this
random selection scheme. The random selection was con-
ducted to reduce the possibility that the RA might selec-
tively choose patients to include in the study that could
affect the outcome of the study, i.e., reduce selection bias.
The RAs screened the ED medical records in the ambula-
tory care and urgent care areas of the ED looking for
patients who potentially met the study eligibility criteria.
Patients in the critical care, substance abuse, and psychiat-
ric evaluation areas of the ED were not screened for study
inclusion. The demographic profile (age, gender, race/eth-
nicity, marital status, and insurance type) for every patient
screened was recorded into the study database. The RAs
also recorded the reasons for exclusion from the study and
did not approach those who were ineligible by ED medi-
cal record review.
Patients who appeared to meet eligibility criteria by med-
ical record review were approached by the RA. The RA
briefly outlined the study purpose to the patient and
asked for their verbal consent to confirm their demo-
graphic profile, study eligibility, and to ask additional
questions about their HIV testing history and HIV status.
Patients who declined to answer these questions or who
were found to meet exclusion criteria during this brief
interview (e.g., told the RA that they were HIV-infected)
were excluded from the study. The RA recorded the rea-
sons for their exclusion. Patients who met study eligibility
were apprised of the study and invited to participate. Ver-
bal agreement to participate was obtained.
In Trial One, patients were randomized to an in-person
discussion on rapid HIV testing information arm or a no-
information arm. The no-information arm received no
rapid HIV pre-test information of any type. In Trial Two,
patients were randomized to an in-person discussion arm
or a video arm. The RA randomized patients for each trial
using their penultimate medical record number. Odd-
numbered patients were assigned to the in-person discus-
sion while even-numbered patients were assigned the
other arm, respective to the trial. Following the delivery of
rapid HIV test information (or no information), the RA
orally administered an identical questionnaire to all par-
ticipants to assess their comprehension on the material
presented. At the completion of the questionnaire,
respondents were given an opportunity to discuss any
questions or concerns about the material or topics pre-
sented or the study itself. At the completion of the study,
participants were provided a copy of the written consent
summary and a brochure on HIV and HIV testing that also
gave a list of locations in the local area where they could
be tested for HIV.
Rapid HIV pre-test information delivery
For both trials, the in-person discussion was a semi-
scripted conversation between the participant and RA on
five topics: HIV and AIDS, HIV transmission, HIV preven-
tion, HIV testing, and rapid HIV testing. An outline of the
points covered in the in-person discussion is provided in
Figure 1. The outline was created by the study authors and
is based upon CDC recommendations for pre-test infor-
mation [8] as well as manufacturer details on rapid HIV
testing with OraQuick® [12]. RAs conducting the study
memorized the outline and were trained to deliver it
through mock-interviews. The principal investigator
observed the RAs during the trials, critiqued their per-
formance, and corrected deviations from the outline. The
RAs also underwent training by the state department of
health to be certified as HIV test counselors.
The in-person discussion resembled a didactic presenta-
tion yet was conducted in a conversational style. Partici-
pants were asked an opening question for each of the five
topics. The RA would endorse or correct the participant's
response then state the points relevant to that topic---
whether or not the participant answered the opening
question correctly. To ensure uniformity of the presented
information, the RA limited the discussion to the outline.
The RAs had an abbreviated version of the outline in Fig-
ure 1 to use as a reference during the in-person discussion,
but were not permitted read the outline verbatim to
patients.
In Trial Two, the video information arm patients watched
the 9.5 minute animated and live-action educational
video "Do you know about rapid HIV testing?"[10] that
contained the same rapid HIV pre-test information ele-
ments presented to the in-person discussion arm. The
video and its development are described in the accompa-
nying manuscript: Development of the rapid HIV testing
video, "Do you know about rapid HIV testing?" [see Addi-
tional file 1]. Participants randomized to the video arm
watched the video on a hand-held Tablet PC while await-
ing medical care in the ED. They listened to the video
using headphones provided by the RA.BMC Public Health 2007, 7:238 http://www.biomedcentral.com/1471-2458/7/238
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Assessment of participant comprehension of rapid HIV 
testing fundamentals
Participants in both trials were asked to complete the
"HIV pre-test information comprehension" questionnaire
to assess their comprehension of rapid HIV testing funda-
mentals. The development of the 26-item, "true", "false",
"I don't know" questionnaire is described in the accompa-
nying manuscript: Development of the "HIV pre-test
information comprehension" questionnaire [see Addi-
tional file 2]. Participants in both trials received the iden-
tical version of the questionnaire. The RAs administered
the questionnaire verbally to participants and recorded
the responses onto a Tablet PC database. RAs provided all
participants with a standardized, brief introduction to the
nature of the questions, the reason for the questionnaire
("to determine how well we were able to give you this
information about HIV and rapid HIV testing"), and the
form of the responses needed ("true", "false", or "I don't
know"). The RAs also informed participants that they
would not be able to assist in answering the questions
during the administration of the questionnaire, but could
repeat questions as needed. Participants were asked to
choose the response they thought was best, but to feel free
to answer any question as "I don't know" when unsure of
an answer. The RAs discussed the questions and answers
with the participants after they completed the question-
naire.
Data collection and analysis
The RAs recorded all study data (demographic and HIV
test history, eligibility determinations, responses to the
questionnaire, etc.) onto a Tablet PC study database using
the QDS® (NOVA Research, Bethesda, MD) data entry and
management software. To ensure accuracy of the data
In-person discussion rapid HIV pre-test information outline Figure 1
In-person discussion rapid HIV pre-test information outline.
I’d like to talk to you about HIV and HIV testing, particularly about HIV testing with the 
OraQuick® rapid HIV test.  We’ll talk about what HIV is, how it’s passed, and how it can be 
prevented. We’ll also talk about HIV testing and the benefits and consequences of testing. 
If you are confused by anything that I say, feel free to ask for me to explain, but I may 
hold of some of your questions until later.  Do you have any questions before we begin? 
What can you tell me about HIV? (Definition of HIV/AIDS) 
x HIV stands for the Human Immunodeficiency Virus.   
x HIV is the virus that causes AIDS. 
x AIDS stands for the Acquired Immune Deficiency Syndrome. 
x HIV and AIDS are related, but they are not the same thing.  When you get HIV, your 
body can get diseases easily, diseases which it could normally fight off, because your 
immune system gets damaged. Your immune system is what normally works to keep 
you healthy.   When you get these diseases, you’re said to have developed AIDS.     
What can you tell me about how people get HIV? (HIV Transmission) 
x HIV is passed from person to person--from an infected person to an uninfected 
person.
x HIV can be passed by certain body fluids: blood, semen, vaginal fluids, and breast 
milk.   
x HIV can be passed through sex – anal, oral, or vaginal sex-- or by sharing injection-
drug needles. Also, a mother who has HIV can pass HIV to her baby during birth or 
breast feeding.  The more often you share needles or have sex without condoms, the 
greater your risk of getting HIV.  
x HIV cannot be passed through sweat, saliva, or tears. You cannot get HIV through 
“everyday” contact, such as touching, holding hands, kissing, sharing dishes, or 
sharing a bathroom. 
x Anyone can become infected with HIV. 
Do you know how to prevent getting HIV? (HIV Prevention) 
x HIV can be prevented by using condoms for sex or not having sex, not sharing 
equipment and needles, or by cleaning injection-drug needles and equipment with 
bleach and water.  Also, pregnant mothers who have HIV can take medications to 
reduce the risk of passing HIV to her unborn child and can make sure not to breast 
feed after the child is born. 
x There is no cure or vaccine for HIV, but treatment is available. 
How can you tell if someone has HIV? (HIV Testing) 
x The only way to tell if someone has HIV is to take an HIV test.   
x Even once people have gotten HIV; it may be 5-10 years or more before they have 
any symptoms. Someone can look at feel completely healthy and yet have HIV.   
x Many people are HIV infected and do not know it.  These same people, however, can 
pass HIV on to others.  
Why do you think someone might want to get tested for HIV? (Benefits of Testing) 
x Relieve the worry/stress of not knowing  
x You can get early HIV treatments, if you discover that you have HIV 
x You can get the appropriate treatment from your doctor 
x If someone finds out they have HIV, they can take steps to prevent giving it to  
       someone else 
Why do you think someone might not want to get tested for HIV? (Consequences of Testing) 
x The testing process and test results may be stressful
x There have been problems in the past getting certain types of jobs and certain types 
of insurance for people with HIV, but there are programs available now to help people 
with those issues.
Do you know how an HIV test works? (HIV Testing) 
x HIV tests check for antibodies against HIV.   
x Antibodies are made by your body to help fight infection, and antibodies are a marker 
for having a specific disease or infection, like HIV.   
x HIV antibodies are made up to several months after being infected with HIV, so it 
might be as long as 3-6 months after getting HIV before an HIV test would detect 
them.  So, if you are worried you might have gotten HIV in the last 3 months, you 
might want to think about getting another test 3 months from now. 
Do you know what kinds of HIV tests are available? (Rapid HIV Testing) 
x There are two main types of HIV tests: standard and rapid.   
x Standard tests usually take 1-2 weeks to get test results, and often use a sample of 
blood taken from your arm.   
x Rapid tests allow you to get a preliminary test result the same day.  With the 
OraQuick® rapid HIV test we’re offering today, we will use a small finger prick of 
blood, and the test will run for about 20 minutes, so you can get your results before 
you leave.  The way the test works is this: 
o I will clean your finger with a antiseptic wipe and prick it with a lancet
o I will take a drop of your blood with a small loop
o I will mix this blood in a solution and then take it to be tested
x There are 3 possible test results: negative, preliminary positive, and invalid 
o A negative test result means that no HIV antibodies were found in your blood. 
However, if you have been exposed to HIV within the last three months, this test 
would not detect it.  So, you may want to think about having another HIV test a 
few months from now if you think you may have been exposed to HIV. 
o A preliminary positive means that the rapid test detected HIV antibodies in your 
blood, but it is not the final answer. You need a second test to confirm the 
results. It will probably take about one week to get these confirmatory results.   
o Although rare, an invalid test result means that there was a problem with the test 
itself, and is not related to whether or not you have HIV.  A second test will need 
to be performed in order to know if you’re HIV infected. 
Recap: 
x HIV causes AIDS, but they are not the same 
x HIV can be passed from person to person through sex without a condom or sharing 
needles
x HIV can be prevented by using condoms, not having sex, not sharing needles, or 
using clean needles 
x There are many benefits to being tested for HIV 
x With the OraQuick® rapid HIV test, you can find out your results the same day, 
however a preliminary positive test result will require a second test to confirm the 
results BMC Public Health 2007, 7:238 http://www.biomedcentral.com/1471-2458/7/238
Page 5 of 12
(page number not for citation purposes)
entry, the data were entered in duplicate with immediate
data verification. The data were analyzed using Stata 9.2
(Stata Corporation, College Station, TX). The analysis
included tabulating the results of the medical record
screening and eligibility determinations; participant
demographic profiles, educational level, and HIV testing
histories; and responses to the "HIV pre-test information
comprehension" questionnaire. Patients were compared
by their demographic profiles according to their eligibil-
ity, participation, and study arm assignment using Pear-
son's χ2 test for categorical values; Fisher's exact test for
categorical values with small samples; two-sample tests of
binomial proportions for dichotomous values; and Wil-
coxon rank-sum test for continuous values. Participant
educational level and HIV testing history were compared
by study arm assignment using Pearson's χ2  test and
Fisher's exact test.
The mean score and standard deviation, median, and
range for each of the five topics areas of the questionnaire
and the entire questionnaire were calculated by arm
assignment for both trials. We originally estimated requir-
ing a sample size of 55 for each arm of Trial Two to dem-
onstrate a 12% absolute increase in mean scores. We
assumed the same standard deviation for each arm, a nor-
mal distribution of scores, α = 0.05, β = 0.10, and use of
Student's t-test. However, using plots of the scores for each
trial and the Wilk-Shapiro test, we observed that the scores
were not normally distributed, therefore, the scores for the
arms were instead compared using the Wilcoxon rank-
sum test. Differences were considered significant at the α
= 0.05 level. In an exploratory analysis, the proportions of
participants answering each question correctly were com-
pared by arm assignment using two-sample tests of bino-
mial proportions. This exploratory analysis was used to
help identify sub-topics that might not have been well
addressed in the pre-test information stage or highlight
questions that might not have been well understood by
participants.
Results
Study participant demography and HIV testing history
Trial One
Figure 2 depicts the results of the screening and enroll-
ment for Trial One. Of the 349 ED patients whose medical
records were randomly screened for Trial One, 88 were eli-
gible for participation. The primary reason for ineligibility
was age < 18 or age > 55 years (50.6%). Twenty patients
declined or did not complete the screening process. Of the
88 patients who completed the screening process with the
RA and were eligible for the study, 73 originally agreed to
be in the study. Of these, 34 patients were randomized to
the in-person discussion and 39 to the no-information
arm. Three people randomized to the in-person discus-
sion arm and one in the no-information arm dropped out
of the study.
Table 1 provides a comparison of the demography and
HIV testing history of the patients by whether or not they
participated in the study and by study arm. The partici-
pant and non-participant groups and the in-person dis-
cussion and no-information arms had similar
demographic and HIV testing history profiles. Most of the
participants were male, white, single/never married, had
governmental insurance (Medicaid, Medicare, or both),
had twelve or fewer years of formal education, and had
previously been tested for HIV. Of those who had ever
been tested for HIV, 40.4% had been tested within the
prior year. The participants in the two arms were similar
in their profiles except for partner status and time elapsed
since their last HIV test. There were relatively more single/
never married and separated participants in the no-infor-
mation arm and relatively more married and divorced
participants in the in-person discussion arm. There were
relatively more participants who had been tested within
the past six months in the no-information arm.
Trial Two
Figure 3 depicts the results of the screening and enroll-
ment for Trial Two. Of the 1,062 ED patients whose med-
ical records were randomly screened for Trial Two, 216
were eligible for participation. The primary reason for
ineligibility was age < 18 or age > 55 years (47.9%). Forty-
four patients declined or did not complete the screening
process. Of the 216 patients who completed the screening
process and were eligible for the study, 120 originally
agreed to be in the study. Of these, 62 were randomized
to the in-person discussion and 58 to the video arm. Three
people randomized to the in-person arm and three to the
video arm dropped out of the study.
As shown in Table 2, Trial Two participants and non-par-
ticipants had similar demographic profiles. There were
more non-participants who had not been previously
tested for HIV. Most of the participants were male, white,
single/never married, had private healthcare insurance,
had twelve or fewer years of formal education, and had
previously been tested for HIV. Of those tested for HIV,
43.2% had been tested within the past year. The two ran-
domized arms were similar in their demographic and HIV
history profiles.
Rapid HIV testing comprehension
Table 3 shows by arm assignment the percentages of par-
ticipants correctly answering the "HIV pre-test informa-
tion comprehension" questions. The results of the two-
sample tests of binomial proportions are provided in an
exploratory analysis to identify potential sub-topics or
questions that might not have been well understood byBMC Public Health 2007, 7:238 http://www.biomedcentral.com/1471-2458/7/238
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participants. Across both trials, there were twelve ques-
tions correctly answered by more than 50% of the patients
in all arms and five correctly answered by more than 75%
of patients in all arms. Fewer than 50% of participants in
all arms were able to correctly answer the questions
regarding the role of HIV antibodies (question 15) and
phlebotomy for the rapid HIV test (question 25).
Compared to the no-information arm in Trial One, the
percentage of participants in the in-person discussion arm
with correct answers to the questionnaire was significantly
greater statistically for ten of the questions, but was greater
in absolute value for twenty-three of the questions. Com-
pared to the in-person discussion arm, the percentage of
patients in the no-information arm was greater in abso-
lute value for two questions and was the same as the in-
person discussion arm for one question. There were two
questions for which the percentage of correct responses
was ≤50% in the in-person discussion arm as opposed to
fourteen in the no-information arm.
Compared to the in-person discussion arm in Trial Two,
the percentage of participants in the video arm with cor-
rect answers to the questionnaire was not significantly
greater statistically for any of the questions, but was
greater in absolute value for eighteen of the questions. The
percentage of participants in the in-person discussion arm
was significantly greater statistically than for participants
in the video arm for one question (question 3), but was
greater in absolute value for seven other questions. For
both arms of the trial, there were two questions (ques-
tions fifteen and twenty-five) for which the percentage of
correct responses was ≤50%.
Table 4 depicts the mean, median, and range of scores by
arm assignment and subject area for the "HIV pre-test
Table 1: Demographic and HIV testing history profiles: Trial One
Non-
participants
Participants p-value In-person discussion arm No information 
arm
p-value
n = 15 n = 73 p≤ n = 34* n = 39* p≤
Median age (Range) 40 (19–54) 35 (19–55) 0.27 38 (19–55) 34 (19–55) 0.14
%% % %
Gender 0.45 0.60
Female 33.3 43.8 52.9 59.0
Male 66.7 56.2 47.1 41.0
Ethnicity/Race 0.75 0.96
Black 20.0 30.1 32.4 28.2
Hispanic 6.7 5.5 5.9 5.1
White 73.3 61.6 58.8 64.1
Other 0.0 2.8 2.9 2.6
Partner status 0.19 0.04
Single/never married 26.7 52.1 41.2 61.5
Married 46.7 27.4 38.2 17.9
Divorced 26.6 12.3 17.7 7.7
Separated 0.0 5.5 0.0 10.3
Unmarried couple 0.0 2.7 2.9 2.6
Insurance status 0.46 0.09
Private 20.0 34.2 35.3 33.3
Governmental 46.7 43.8 53.0 35.9
Private/Governmental 6.6 1.4 2.9 0.0
None 26.7 19.2 8.8 28.2
Don't know 0.0 1.4 0.0 2.6
Years of formal education 0.16 0.43
Grades 1–8 6.6 1.4 0.0 2.6
Grades 9–11 6.7 21.9 17.7 25.6
Grade 12 or equivalent 60.0 41.1 38.2 43.6
College 1–3 years 26.7 21.9 23.5 20.5
College 4 years 0.0 13.7 20.6 7.7
Prior HIV test 0.19 0.99
Yes 53.3 64.4 64.7 64.1
No 40.0 35.6 35.3 35.9
Don't know 6.7 0.0 0.0 0.0
Time elapsed since last HIV test n = 8 n = 47 0.21 n = 22 n = 25 0.03
> 5 years 0.0 17.0 18.2 16.0
> 2 years ≤ 5 years 37.5 21.3 31.8 12.0
> 1 year ≤ 2 years 25.0 21.3 27.3 16.0
> 6 months ≤ 1 year 0.0 14.9 18.2 12.0
≤6 months 25.0 25.5 4.6 44.0
Don't recall 12.5 0.0 0.0 0.0
*Three patients in the in-person discussion and one in the no information arm dropped out from the study after randomizationBMC Public Health 2007, 7:238 http://www.biomedcentral.com/1471-2458/7/238
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information comprehension" questionnaire. As shown
for Trial One, participants in the in-person discussion arm
had greater scores overall and had greater scores for each
of the five subject areas than those in the no-information
arm. The standard deviations for those in the no-informa-
tion arm were also larger, which indicated a wide varia-
tion in ability to answer the questions among those in this
arm. The difference in scores was largest for the rapid HIV
testing section of the questionnaire. For Trial Two, there
was a trend of higher scores in the video than the in-per-
son discussion arm for three of the subject areas. Although
the overall mean score appeared to be 4% larger for the
video than the in-person discussion arm, there was no dif-
ference in these scores at our specified level of statistical
significance and sample size using the Wilcoxon rank-sum
test.
Discussion
The CDC recently recommended routine, universal HIV
screening in US primary care settings and EDs [3]. The
new guidelines for the healthcare setting advocate for the
use of written or oral HIV pre-test information to stream-
line the testing process. Given the many limitations of giv-
ing HIV pre-test information in oral or written form to
patients, we examined if a video could be a good substi-
tute for an in-person discussion.
We found that ED patients randomly assigned to the edu-
cational video, "Do you know about rapid HIV testing?"
demonstrated as good or better comprehension of rapid
HIV testing fundamentals than ED patients randomly
assigned to an in-person discussion. The video we devel-
oped and evaluated is freely available via the internet [10].
We believe that it can be used as a substitute for an in-per-
son discussion for persons undergoing rapid HIV testing,
whether in the ED or other settings. This substitution is
particularly important for resource poor, busy, rapid HIV
testing settings with limited numbers of or access to HIV
counselors.
We also observed that patient knowledge about rapid HIV
testing can clearly be improved in the short term through
an in-person discussion. Our findings also show that
patients who do not receive any type of rapid HIV pre-test
Trial one screening and enrollment diagram Figure 2
Trial one screening and enrollment diagram.
Declined/Did not Complete Eligibility Screening:
n=20 (5.7%) 
Completed Enrollment:
n=73 (83.0%) 
Final sample: 
n=38 (97.4%) 
In-person discussion:
n=34 (46.6%) 
Dropped out:
n=3 (8.8%) 
Declined to be in Study:
n=15 (17.0%) 
Final sample: 
n=31 (91.2%) 
No information:
n=39 (53.4%) 
Dropped out: 
n=1 (2.6%) 
Eligible for Trial One:
n=88 (25.2%) 
Underwent Eligibility 
Screening:
n=349 Did Not Meet Eligibility Criteria: 
n=241 (69.1%) 
Wrong age     50.6%     Unavailable     4.6%
Not English speaking    27.8%     Currently pregnant     2.9%
Psychiatric visit    14.9%     HIV infected     0.8%
Intoxicated   13.7%     Inmate     0.4%
*Percentages do not total to 100% since patients could be ineligible for multiple reasons.BMC Public Health 2007, 7:238 http://www.biomedcentral.com/1471-2458/7/238
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information have much less knowledge about HIV, HIV
transmission, HIV prevention, and HIV testing than those
who undergo an in-person discussion with an HIV test
counselor. It is even more concerning that this knowledge
was low even though the majority of patients had previ-
ously been tested for HIV and presumably received HIV
pre-test information as part of that test. Since rapid HIV
testing involves a few nuances compared to standard HIV
testing, particularly the three possible test results, our
results suggest that some type of information should be
provided to patients prior to their undergoing testing. Our
study results indicate that either an in-person discussion
or a video presentation would satisfy this need. Of course,
the long-term retention of this knowledge was not directly
assessed through this study. Future studies could evaluate
whether or not the knowledge was retained, which might
impact how the information is used to prevent HIV trans-
mission.
This study has a number of limitations. First, the study
was conducted at a single ED in the US and had several
exclusion criteria that reduced the scope of the study pop-
ulation. As a result, the results might not be generalized to
other populations and settings. However, given the diver-
sity of the participants in our study, the random selection
of participants, and the random assignment of partici-
pants to information arms, we believe that our results are
reasonably applicable to most other English-speaking
patient groups. Second, the questionnaire we developed
and employed in this study is not a perfect indicator of
patient comprehension of these topics. There might have
been other areas of difference or even similarity between
arms not measured in our questionnaire. However, the
administration of an identical questionnaire in a stand-
ardized fashion to randomly selected groups helped
ensure that it was a consistent evaluator. Further, the
extensive questionnaire development process helped pro-
Table 2: Demographic and HIV testing history profiles: Trial Two
Non-
participants
Participants p-value Video arm No information 
arm
p-value
n = 96 n = 120 p≤ n = 58* n = 62* p≤
Median age (Range) 38 (18–55) 35 (18–55) 0.21 34 (19–55) 37 (19–55) 0.45
%% %%
Gender 0.62 0.48
Female 50.0 46.7 50.0 43.6
Male 50.0 53.3 50.0 56.4
Ethnicity/Race 0.69 0.09
Black 19.4 14.2 8.6 19.4
Hispanic 11.2 11.7 8.6 14.5
White 66.3 69.1 74.2 64.5
Other 3.1 5.0 8.6 1.6
Partner status 0.35 0.50
Single/never married 41.9 33.3 32.8 33.9
Married 31.6 30.0 31.0 29.0
Divorced 10.2 17.5 22.4 12.9
Separated 5.1 4.2 3.5 4.8
Widowed 1.0 0.0 0.0 0.0
Unmarried couple 10.2 15.0 10.3 19.4
Insurance status 0.99 0.48
Private 44.9 44.2 43.1 45.2
Governmental 34.7 35.8 34.5 37.1
Private/Governmental 1.0 1.7 0.0 3.2
None 19.4 18.3 22.4 14.5
Years of formal education 0.17 0.63
Grades 1–8 5.1 2.5 3.5 1.6
Grades 9–11 30.6 18.3 17.2 19.4
Grade 12 or equivalent 27.6 30.8 36.2 25.8
College 1–3 years 24.5 34.2 32.8 35.5
College 4 years 12.2 14.2 10.3 17.7
Prior HIV test 0.02 0.23
Yes 55.1 68.3 65.5 71.0
No 44.9 29.2 29.3 29.0
Don't know 0.0 2.5 5.2 0.0
Time elapsed since last HIV test n = 54 n = 81 0.95 n = 22 n = 25 0.34
> 5 years 24.1 23.5 24.3 22.7
> 2 years ≤ 5 years 22.2 17.3 16.2 18.2
> 1 year ≤ 2 years 13.0 16.0 21.6 11.4
> 6 months ≤ 1 year 16.7 19.7 10.8 27.3
≤6 months 24.0 23.5 27.1 20.4
*Three patients in each arm dropped out of the study after randomizationBMC Public Health 2007, 7:238 http://www.biomedcentral.com/1471-2458/7/238
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duce a reasonably valid estimator of patient knowledge
on the presented topics. Third, the study was not con-
ducted on patients undergoing rapid HIV testing. It is pos-
sible that patients who know they will be tested would
have a greater stake in listening to the information pre-
sented to them. As a result, differences between the in-per-
son discussion and video arms might be reduced for these
patients. To address this possibility, we are conducting a
larger study comparing in-person discussion to video
presentation among patients being tested for HIV
OraQuick®. Fourth, the study did not show that members
of the video arm had greater mean scores than those in the
in-person discussion arm. A much larger sample size
might have demonstrated a difference. Further, there is
some loss of power to using a Wilcoxon rank-sum test,
which might account for a failure to detect a difference
between the video and in-person discussion arms. Also,
because we originally assumed a normal distribution of
scores and planned our sample size for trial 2 accordingly,
we might have underpowered our study. A non-inferiority
study design might have been a preferable method for
evaluating this trial. For the subsequent larger trial, we
changed the trial design to accommodate a non-inferiority
design. Fifth, the randomization process did not produce
equal size groups and was not concealed to the RA.
Although no significant loss of power is expected, given
the sample size, there is a possibility that the RA could
have encouraged some patients to be in the trial based
upon the type of assignment (video, in-person discussion,
or no information) they were intended to receive. We
expect that this influence is probably small and that more
than likely the imbalance is due to less than optimal allo-
cation of patients into groups.
Trial two screening and enrollment diagram Figure 3
Trial two screening and enrollment diagram.
Declined/Did not Complete Eligibility Screening:
n=44 (4.1%) 
Completed Enrollment:
n=120 (55.6%) 
Final sample: 
n=55 (94.8%) 
In-person discussion:
n=62 (51.7%) 
Dropped out:
n=3 (8.8%) 
Declined to be in Study:
n=96 (44.4%) 
Final sample: 
n=59 (95.2%) 
Video:
n=58 (48.3%) 
Dropped out: 
n=3 (2.6%) 
Eligible for Trial Two:
n=216 (20.3%) 
Underwent Eligibility 
Screening:
n=1,062 Did Not Meet Eligibility Criteria: 
n=802 (75.5%) 
Wrong age     47.9%       Intoxicated     6.6%
Unavailable    22.6%       Inmate     1.9%
Not English speaking    17.6% Currently pregnant     1.4%
Psychiatric visit      7.9% HIV infected      0.8%
*Percentages do not total to 100% since patients could be ineligible for multiple reasons.B
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Table 3: Correct responses on the "HIV pre-test information comprehension" questionnaire
Trial One Trial Two
No information In-person discussion p-value In person discussion Video p-value
n = 31 n = 38 n = 59 n = 55
Question HIV/AIDS Definition %% p≤ %% p≤
1 If you were HIV infected, current drug treatments would let you live 
longer. (T)
86.8 90.3 0.65 83.1 89.1 0.36
2 People can get AIDS without getting HIV. (F) 36.8 71.0 0.00 86.4 76.4 0.17
3 Being infected with HIV does not mean you have AIDS. (T) 65.8 90.3 0.01 89.8 74.6 0.03
4 A person can be infected with HIV for 5 years or more without getting 
AIDS. (T)
76.3 96.8 0.01 91.5 92.7 0.81
HIV Transmission
5 A person cannot get HIV by donating blood. (T) 39.5 54.8 0.21 57.6 65.5 0.39
6 A woman with HIV can give HIV to her baby during breastfeeding. (T) 68.4 100.0 0.00 98.3 94.6 0.28
7 If someone gets HIV through needle sharing, that person can only 
spread HIV by sharing needles with other people. (F)
63.2 80.7 0.10 79.7 89.1 0.17
8 Coins, such as quarters or nickels, can carry HIV. (F) 68.4 93.6 0.01 98.3 90.9 0.08
9 A person cannot get HIV by putting their tongue in the mouth of 
someone who has HIV. (T)
42.1 61.3 0.11 67.8 81.8 0.08
HIV Prevention
10 HIV is destroyed by bleach. (T) 13.2 58.1 0.00 55.9 52.7 0.73
11 If you use injection drugs, the only way to prevent getting HIV is to quit 
using them. (F)
50.0 64.5 0.22 61.0 65.5 0.62
12 Wearing insect repellant to keep away mosquitoes will help prevent 
you from getting HIV. (F)
81.6 61.3 0.06 86.4 89.1 0.66
13 Not having sex is the only way to reduce your risk of getting HIV. (F) 71.1 74.2 0.77 71.2 74.6 0.68
14 You can prevent getting HIV after sex by washing your genitals or 
private parts. (F)
84.2 83.8 0.96 93.1 96.4 0.43
HIV Testing
15 HIV makes antibodies which harm a person's body. (F) 10.5 19.4 0.31 30.5 23.6 0.41
16 Having blood drawn for an HIV test will make you anemic. (F) 81.6 93.6 0.12 91.5 89.1 0.66
17 The HIV antibody test will help strengthen your antibodies to keep you 
from getting infected with HIV. (F)
76.3 83.9 0.43 83.1 85.5 0.73
18 If you were infected with HIV one week ago, your HIV test will be 
negative. (T)
42.1 61.3 0.11 57.6 80.0 0.10
19 The HIV antibody test will not tell you if you have AIDS. (T) 42.1 42.2 0.99 55.9 69.1 0.15
20 If your HIV test is negative, it must be repeated within a week to 
confirm the results. (F)
31.6 61.3 0.01 54.2 70.9 0.07
Rapid HIV Testing
21 It takes one to two days to perform a rapid HIV test. (F) 18.4 77.4 0.00 81.4 74.6 0.38
22 An invalid rapid HIV test result means you've been infected with HIV 
for fewer than 3 months. (F)
34.2 61.3 0.03 72.9 78.2 0.51
23 If your rapid HIV test is positive, then you will need a test to confirm 
this. (T)
71.1 87.1 0.09 81.4 89.1 0.25
24 The rapid HIV test with OraQuick uses a sample of your urine. (F) 34.2 90.3 0.00 81.4 87.3 0.39
25 A needle can be used to take blood from your arm for the OraQuick 
rapid HIV test. (T)
42.1 45.2 0.80 37.3 38.9 0.86
26 Even if your rapid HIV test is positive, you may not have HIV. (T) 39.5 61.3 0.07 54.2 63.6 0.31BMC Public Health 2007, 7:238 http://www.biomedcentral.com/1471-2458/7/238
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Conclusion
We found that the video "Do you know about rapid HIV
testing?" appears to be an acceptable substitute for an in-
person discussion on rapid HIV testing with OraQuick® in
the ED setting. We also observed that either form of pre-
test information was preferable than providing no infor-
mation. We believe that this freely available video can be
used for patients undergoing rapid HIV testing with
OraQuick® to help inform them about HIV and rapid HIV
testing particularly in resource poor or busy HIV testing
settings, such as the ED.
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No information In-person discussion p-value In-person discussion Video p-value
n = 38 n = 31 n = 59 n = 55
Subject 
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µ (σ)M e d i a n  
(range)
µ (σ)M e d i a n  
(range)
p≤ µ (σ)M e d i a n  
(range)
µ (σ)M e d i a n  
(range)
p≤
HIV/AIDS 
Definition
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Testing
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